Abstract. By means of the tumorigenicity assay applying DNA from a patient with a gastric carcinoma (MA) we have already reported the identification of the putative oncogene myeov. In addition we have shown its involvement in t(11;14)-positive multiple myelomas and amplifications of breast tumours and esophageal carcinomas. The failure of myeov cDNA to induce tumour formation in NIH/3T3 cells prompted us to analyze the human sequences present in our MA-T1a1 tertiary transfectants. Sequence analysis revealed the presence of the human oncogene hst (fgf4) at a distance of ~9kb from the myeov gene in our MA-T1a1 tertiary transfectants. Both myeov and hst (fgf4) are normally situated ~475-kb apart at band 11q13, a region that is frequently amplified and overexpressed in various tumours. Southern and Northern blot analyses confirmed our sequence data and showed rearrangement of hst sequences during the transfection process and its expression in our MA-T1a1 tertiary transfectants.
Introduction
Using the tumorigenicity assay our group was able to identify and/or isolate a plethora of different oncogenes, such as mas, ufo, p85ß/humorf8, ret, cot, tre, hst (fgf4), dbl, B-raf, gef-h1 and myeov (1) (2) (3) (4) (5) . This latter gene, myeov, was identified by the tumorigenicity assay using DNA from the tumour of a patient with gastric carcinoma and assigned to the chromosomal region 11q13. The 11q13 region is involved in genomic/chromosomal rearrangements in a variety of human malignancies, including reciprocal translocations in B-cell neoplasms, unbalanced translocations or chromosomal inversions and frequent DNA amplification in various carcinomas, such as breast tumours, head and neck cancers, oesophageal squamous cell carcinomas (ESC) and many other types of solid tumours (1) . We were able to show that myeov is rearranged and activated concomitantly with cyclinD1 (CCND1) in a subset of human t(11;14)(q13;q32)-positive multiple myeloma cell lines (1) . In a collaborative study, we also showed that myeov is frequently coamplified with cyclinD1 (9.5%) and abnormally expressed (16%) in a number of human breast carcinomas (6). Moreover we elucidated the possible involvement of myeov in ESC carcinogenesis and found that myeov was coamplified with cyclinD1 in a great number of cell lines and primary tumours tested. However, myeov RNA overexpression was only detected in a subset of cell lines carrying myeov amplification, a phenomenon attributed to aberrant methylation of the myeov promoter (7) . Zoo blot analysis and database analyses revealed that the myeov gene is present in humans and chimpanzee, but not in Zebrafish, frog, dog, sheep, mouse or rat. Myeov mRNA expression has only been detected in humans. A computer search with the deduced MYEOV protein sequence did not detect any homology with known protein motifs or domains. Its exact cellular function therefore remains elusive.
The hst/fgf4 gene was originally identified as a transforming gene in DNAs from gastric carcinomas, a noncancerous portion of gastric mucosa and a Kaposi sarcoma by transfection assays using NIH/3T3 cells (8) (9) (10) . Expression of its cDNA in an expression vector and the genomic hst gene induced the transformation of NIH/3T3 cells upon transfection (11, 12) . The mouse homologue of the hst/fgf4 gene has been found to be activated by proviral insertion in some virally induced mammary tumours (13) .
Despite the detection of human myeov DNA sequences and myeov RNA expression in our MA-transfectants, its involvement in t (11;14) translocations in multiple myelomas and its amplification and overexpression in various carcinomas, we were not able to transform NIH/3T3 cells using myeov cDNA. In order to clarify the exact constellation in the thirdcycle transfectant surrounding the myeov gene we determined the complete sequence of the alu-positive phage clone.
Materials and methods
Cell lines. The murine fibroblastic cell line (NIH/3T3) was originally obtained from M. Wigler (14) . The cells utilized in transfection assays (see below) were derived from a single clone (B 2 5) selected by us on the basis of flat morphology, low incidence of spontaneous overgrowth, and ability to transform efficiently with T24 bladder carcinoma DNA containing an activated H-ras gene (15) . NIH/3T3 cells were propagated in Dulbecco's modified Eagle's medium supplemented with 10% NCS and antibiotics. Cell lines were propagated in a humidified CO 2 incubator with 5-7% CO 2 at 37˚C.
Transfection assay. High molecular weight DNA of a stomach cancer was cotransfected into NIH/3T3 cells together with a dominant drug-resistant selectable marker, pRSVneo, followed by G418 selection and injection of the resulting colonies into nude mice, as described (16) .
Genomic cloning. DNA isolated from a third-cycle induced mouse tumour MA-T1A1 was partially digested with Sau3AI, treated with calf intestine phosphatase, fragments fractionated by size using NaCl or sucrose gradients, ligated to phage (EMBL-3) arms (17) , packaged in vitro, plated and screened with a human alu probe (4, 18) . Genomic subfragments of an alu-positive phage were sub-cloned into digested pT7T3 plasmid DNA (Amersham Pharmacia Biotech, Freiburg, Germany).
DNA and RNA purification and analysis. High molecular weight DNA from cell lines or phage clones was prepared according to standard methods. DNA was digested with restriction endonucleases, electrophoresed on a 0.6% agarose gel and blotted onto Nytran 13N membranes (Schleicher and Schuell, Dassel, Germany). Filters were hybridized in 3X SSC (0.45 M NaCl, 0.045 M sodium citrate), 5X Dennhardt's, 200 μg/ml denatured salmon sperm DNA, 1% SDS and 10% dextran sulphate at 63˚C for 16 h with randomly primed 32 Plabelled probes (MBI Fermentas, St. Leon-Rot, Germany) with 2 μg/ml pRSVneo DNA as competitor DNA to avoid cross-hybridization with cotransfected pRSVneo sequences. Subsequently the filters were extensively washed in 3X SSC, 0.1% SDS at 63˚C, followed by a moderate or high stringency wash. Filters were exposed to Kodak X-Omat DS, XAR-5, or MS-film at -70˚C with Ilford intensifier or MS screens (5) . For hybridization analysis we used the following insert probes; 300-bp insert from the human repetitive specific alu plasmid Blur-8 (19), a 285-bp SacI-HindIII fragment from the pORF1 plasmid containing hst cDNA, a 5' EcoRI myeov cDNA fragment and a rat GAPDH cDNA sequence. Total RNA was isolated and purified by acid guanidinium isothiocyanate/phenol-chloroform extraction, as described (20) . PolyA + RNA was purified using an Oligotex mRNA mini kit (Qiagen GmbH, Hilden, Germany) per the manufacturer's instructions. Northern blot analyses were performed as described by Shackleford and Varmus (21) . Briefly, comparable amounts of polyA + RNA were resolved on 1.2% agarose formaldehyde gels, blotted on to Hybond-N membranes (Amersham Pharmacia Biotech) and then hybridized as described for Southern blotting.
DNA sequencing. Plasmids containing large inserts were sequenced by application of the EZ::TN™ <TET-1> insertion system, based on the Tn5 transposition system (22) . This system permits high efficiency, random insertion of an EZ::TN™ Transposon into DNA target molecules in vitro and accelerates sequencing of large DNA templates. As the primers supplied by the manufacturer (TET-1 FP-1 and RP-1) failed to provide the expected results, we developed a new primer set (TET-1 rev 2:5' IRD700-gtaccgagctcgaattcatcg 3' and TET-1 FP-2:5' IRD800-gtcgacctgcaggcatgc 3') from the EZ::TN™ <TET-1> Transposon sequence that gave good results using a LI-COR long Readir 4200.
Plasmid miniprep DNA samples were sequenced with a Reader™ Taq polymerase fluorescent-labelled primer CycleReader™ auto DNA sequencing kit with 7-deaza-dGTP (MBI Fermentas) on a LI-COR long Readir 4200 DNA sequencer. 
Results
Using DNA from a gastric carcinoma (MA) in the NIH/3T3-transformation/tumorigenicity assay we were able to induce tumours in nude mice with a latency period of 6 weeks. Southern blot analysis of DNA obtained from a tertiary nude mouse tumour exhibited a consistent pattern of human alu repeat sequences after digestion with the restriction enzyme EcoRI (Fig. 1) . DNA of a tertiary transfectant was cloned into the EMBL-3 phage vector and probed for human sequences using human alu-repetitive sequences. One single alu-positive phage clone was isolated. Exon-trap analysis of genomic subfragments from this alu-positive phage clone revealed a 400-bp exon-trap fragment that was used for Northern blot analysis and detected two transcripts in RNA of a third-cycle transfectant (MA-T1A1) but not in normal NIH/3T3 cells. cDNA cloning enabled the cloning of a novel putative transforming gene called myeov (1) . In addition we showed overexpression of myeov as a consequence of a specific chromosomal translocation in multiple myelomas (1) and amplification and overexpression of myeov in oesophageal squamous cell carcinomas (ESC) (7) and breast tumours (6) . Although these data convincingly support a causal role for myeov in NIH/3T3 transformation and cancer, we were not able to confirm its potency to elicit a transformed phenotype in NIH/3T3 cells by means of overexpression of full-length myeov cDNA. To resolve this apparent contradiction we decided to determine the complete sequence of the only alupositive phage clone of the third-cycle transfectant (MA-T1A1) that we were able to isolate. In addition to the presence of myeov sequences, database analysis revealed the presence of hst sequences in this alu-positive phage clone (Fig. 2) . As mentioned above, hst was detected by the NIH/3T3 transformation assay using DNAs from different tumours (8, 9) . The transforming capacity of hst in NIH/3T3 cells has been proven (10, 11) . Both myeov and hst are located on chromosome 11 band q13.1 at a distance of ~475 kb. In the MA-T1A1 tertiary transfectants two fragments of the 11q13.1 region (AP005232.3 and AP006345.3) containing the myeov and hst genes are joined, respectively. In this situation the myeov gene DNA and hst gene DNA are located at a distance of ~9 kb from each other.
To resolve the mechanism of activation of the hst (fgf4) gene and to confirm our sequence data, we performed Southern blot analysis. DrdI-digested DNA from two healthy individuals, the original stomach tumour as well as DNA from a tertiary MA-T1 transfectant and NIH/3T3 control cells was hybridized with a probe containing the 3' portion of hst (fgf4) cDNA (Fig. 3) . In the two healthy individuals and in the original gastric carcinoma, hst (fgf4) hybridised with a DrdI fragment of ~11 kb, which exactly corresponds to the original genomic constellation in the ensemble database. DNA of our tertiary MA-T1a1 transfectant showed three bands, namely of ~16.8 kb, ~8 kb and ~1.8 kb. The two smaller bands are also present in DNA of NIH/3T3 cells and therefore represent the murine homologue of the hst (fgf4) gene. The higher band of ~16.8 kb represents rearranged human hst sequences in DNA of our MA-T1a1-transfectant and matched perfectly with our sequence data.
To confirm our data we performed a Northern blot analysis. RNA of the MA-T1a1-transfectant, an hst-negative transfectant and hst-positive transfectant (5), both serving as controls were hybridized with the hst (fgf4) probe. Our Northern blot data revealed hst (fgf4) transcripts in RNA of the hst-positive transfectant as well as in RNA of the MA-T1a1 transfectant and thus confirmed our Southern blot and sequence data. RNA of the MA-T1a1 transfectant shows the expected and previously described myeov transcripts (1).
Discussion
The application of the NIH/3T3 transformation assay and its variants has allowed us and others to detect several oncogenes exhibiting diverse functions. Except for the ras genes most genes became activated by truncation, loss of gene or regulatory sequences or gene fusion. In some cases the oncogenes were already activated in the original tumour prior to gene transfer, i.e. the ras genes in various neoplasias, the met gene in the MNNG-HOS cell line (23), the erbB2 (formerly neu) in ENU-induced rat neuroblastomas (24) and the trk oncogene in a human colon carcinoma (25) .
The presence of unrelated DNA fragments originating from different regions of the human genome in tumour/ transfectant DNAs has already been reported by us and others, i.e. gef-h1(2) and mcf-2, an activated form of the dbl oncogene (26, 27) . In these cases fragments derived from different chromosomes were joined together and integrated as a transgenome into the genome of murine NIH/3T3 cells. Considering the size of the human-and/or mouse genome, the fact that NIH/3T3 can take up ~5000 kb of DNA by calcium phosphate transfection and that the size of purified genomic DNA fragments is ~50-100 kb, human DNA sequences present in tertiary NIH/3T3 transfectants should have a size of ~50-80 kb and contain the activated human oncogene. An addition of the sizes of alu-positive fragments detected by Southern blot analyses in different NIH/3T3 transfectants supports this assumption (Fig. 1) (28) . The complete sequence of a human transgenome, including its murine boundaries in a tertiary transfectant of the monocytic leukaemia cell line U937 proved that this assumption is correct (2) . The myeov gene detected by us through application of the NIH/3T3 tumorigenicity assay to DNA from a gastric carcinoma possessed features that were also found for other oncogenes detected by this assay. The myeov gene was present on the human transgenome, highly expressed in its transfectants and not expressed in normal NIH/3T3 cells (1) . In addition we showed that myeov was situated near a common t(11;14)(q13;q32) breakpoint in multiple myelomas and showed overexpression in a subset of these t(11;14)-positive multiple myeloma cell lines. Moreover we showed amplification and overexpression of myeov in breast cancer and in oesophageal squamous cell carcinomas (6,7). Unfortunately we were not able to show any morphological transformation or tumour induction of NIH/3T3 cells transfected with myeov cDNA. In fact this prompted us to completely sequence an alu-positive phage clone obtained from tertiary MA-T1a1 transfectant DNA. Our sequence analysis revealed the presence of human hst (fgf4) sequences in the tertiary MA-T1a1 transfectant DNA. The hst/fgf4 gene was originally identified as a transforming gene in DNAs from gastric carcinomas, a noncancerous portion of gastric mucosa and a Kaposi sarcoma by transfection assays using NIH/3T3 cells (8) (9) (10) . Our data therefore suggest that hst sequences were responsible for tumour induction in nude mice within our tertiary MA-T1a1 transfectants. It has been reported that genomic clones with 38-40 kb inserts and containing the hst (fgf4) gene of normal human DNA were capable of transforming NIH/3T3 cells. The loss of silencer or suppressor sequences located far from the coding sequence would activate its expression (29, 30) . We suggest a similar activation process in our MA transfectants.
On the other hand, it may be possible that myeov has an additive or synergistic effect. Both myeov and hst are located on 11q13, a frequent site of genetic aberration in a number of human malignancies, especially breast and head and neck cancers (31) . Several candidate oncogenes have been proposed, i.e. myeov, cyclinD1, ems1 and a recently characterized emsy gene in human breast cancer cell lines and primary tumours that binds to brca2 (6, 32, 33) . It is proposed that several genes are responsible for the amplifications at 11q13, because at least four distinct cores of amplification have been recognized and amplification profiles vary according to tumour type (33) (34) (35) . In this study we report the joining of two fragments that are normally separated ~475 kb in one transgenome in MA-T1a1 transfectants. Southern blot data revealed a band of similar size in DNA of two healthy individuals and the original stomach cancer implying that no rearrangement occurred in DNA of the original stomach tumour (Fig. 3,  lanes 1-3) . During transfection DNA fragments can and are randomly ligated to any other DNA fragment. The probability that two specific DNA fragments with a size of ~40 kb are joined is ~1/100,000. Whether it is just a coincidence that two fragments of 11q13 are joined together in one transgenome in our MA-T1a1 transfectants or whether myeov may potentiate hst transforming activity remains to be determined. Recent studies reported a role for myeov in gastric and colorectal cancer and may therefore support this assumption (36, 37) .
Our data also show that the interpretation of DNA transfection results may not always be definitive, especially if the gene under scrutiny does not possess any transforming capability in NIH/3T3 cells. In these cases a thorough investigation, such as a sequence analysis, of all the human material present in a tertiary transfectant should be performed.
